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Introduction
Asthma is a leading cause of morbidity and can often
lead to hospitalisation and in some severe cases, death.
Asthma burden has both health system and social
costs. Clearly, in countries with a high prevalence of
asthma, health resource utilisation will be greater than
countries with lower prevalence. The Australian
Bureau of Statistics estimates that asthma prevalence
in 2004–2005 was 10% (2 million people) using the
National Health Survey (1). Australia has previously
been reported as having the second highest prevalence
of self-reported wheeze in adults 20–44 years of 41
countries surveyed in the extended European Commu-
nity Respiratory Health Survey (2). Kenny et al. (3)
reported that in a prospective, longitudinal study of
245 asthma patients aged 5–75, the greatest costs to
the health system were driven by admitted hospital
care. The minority of patients who required such
treatment, substantially skewed the cost distribution as
the majority of patients only utilised general practice
treatment. In a cost-effective evaluation in Australia,
Simonella et al. (4) calculated that optimal asthma
treatment and compliance would avert the need for
interventions such as hospitalisation, with a 69% sav-
ing of the current cost burden.
This analysis of the asthma admissions and mor-
tality rates within the Australian hospital system for
the years 2000–2001 to 2004–2005 inclusive gains
greater insight into current asthma burden and pro-
vides a better understanding of the asthma popula-
tion requiring hospital treatment. The population of
admitted patients is described by age, gender and
comorbidities. Length of stay and season of death are
also reported.
Methods
Data was taken from the Australian Institute of
Health and Welfare database run in collaboration
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SUMMARY
Objectives: This study was designed to report factors associated with asthma
hospital admission, such as patient characteristics, type of admission and subse-
quent outcome i.e. discharge or death, for the years 2000–2005. These data are
used for health economic models regarding asthma burden in the hospital setting
in Australia. Methods: Data was obtained from the Australian Centre for Asthma
Monitoring using their amalgamated dataset from all states and territories. Admis-
sions under ICD-10 codes J45 ‘Asthma’ plus all subcodes, and J46 ‘acute severe
asthma’ were included. Codes for associated comorbidity at the time of admission
were identiﬁed, as well as the month of death, age, gender and length and the
type of stay. Conﬁdence intervals for death rate assumed a binomial distribution
because of the rarity of event. Results: The total number of all-cause deaths for
the 5-year observation period was 289 from 202,739 asthma separations or
0.14% or 143 deaths/100,000 separations and the highest rate was seen in
patients over 45 years. Acute upper respiratory tract infections were reported in up
to 25% of all asthma hospital admissions. Length of stay was up to a mean aver-
age of 10.2 days in patients who died (SD 15.3). In 5 years observation there was
152,758 emergency asthma admissions which contributed greatly to Australian
healthcare burden. Conclusions: The study demonstrates that emergency admis-
sions dominate asthma care in the hospital setting in Australia, which suggests
poor asthma control in some patients with subsequent economic burden. Asthma-
related mortality remains a risk for speciﬁc patients in the hospital setting.
What’s known
To date Australian asthma fatality data has been
reported by ACAM, but not speciﬁcally with the
idea of comparison with UK or US studies run with
similar methodologies, and with the purpose of
identifying areas of highest burden within the
hospital systems and the risk factors associated
with mortality in asthma patients.
What’s new
This study provides the additional data for
international comparison as it evaluates the
admission type and asthma disease burden by ICD
code, and describes the population both admitted
and at risk of all-cause mortality.
doi: 10.1111/j.1742-1241.2007.01559.x
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a group set up to assist in reducing the burden of
asthma in Australia by developing, collating and
interpreting data relevant to asthma prevention,
management and health policy. The database con-
tains the asthma public and private hospital inpa-
tient information from all Australian states and
territories. Data in this study runs from 1st July
2000 until 30th June 2005. In Australia hospital
events are reported as ‘separations’. Rates are pre-
sented per number of separations and may not
correspond to actual patient numbers as patients
may have more than one separation per episode or
admission period. Data was not available at the
patient level.
Australia uses ICD-10 coding where J45 codes as
J45.0-allergic asthma, J45.1-non-allergic asthma;
J45.8-mixed asthma, J45.9-asthma unspeciﬁed and
J46 refers to acute severe asthma ‘status asthmaticus’.
Coding is applied by a medical coder after patient
discharge. Medical coders are not physicians and
merely apply codes based on the information con-
tained within the medical record. However, as it is
not known how rigorously the codes are applied, it
was decided to limit reporting here to J45 codes
combined and J46 codes respectively. It is thought
that the application of these codes is reasonable,
although clearly it cannot be guaranteed as to their
100% accuracy. This is a limit of any database used
for epidemiological analysis. In the database J45 and
J46 codes are also divided into elective and emer-
gency events. Emergency does not necessarily corre-
spond to an admission via the emergency
department but the term refers to an event where
care or treatment, in the opinion of the treating phy-
sician, must occur within 24 h of examination i.e. as
a matter of relative urgency. Where the number of
separations is £ 5, the number is not reported
because of conﬁdentiality rules in place within the
Australian data protection system, as it is believed
that individuals may be able to be identiﬁed from
such small numbers. Ethical permission was not
required for this study as the data is anonymised and
the patient identiﬁcation is impossible in the way it
is aggregated.
Results are reported by age band where appropri-
ate, namely; 0–11; 12–16, 17–44 and ‡ 45. These age
bands were selected based on common prescribing
banding for asthma medications and to also catego-
rise patients by age groups that have differing mor-
tality and morbidity risks in the general population,
as it is important to apply such risk criteria to the
clinical population. We did not attempt to further
divide the older age band as number of events such
as mortality are very low within each strata and it
was not felt appropriate to categorise further.
No exclusion criteria were applied to the selection
of data, to reﬂect the real world scenario. Mortality
that occurred during the admission spell (the period
from a live admission to either death or discharge)
were reported. Death is for all cause as it is not pos-
sible to obtain the death certiﬁcate to verify the cause
of death from this database. We were not able to
assess medication use in this study, as the pharmacy
records of the patients were not held as part of the
admission or discharge records. We are therefore not
able to ascertain if cause of death was in any way
related to care or treatment, either prior to, or dur-
ing the hospital episode. We were additionally not
able to assess smoking or allergy status as these are
not recorded in the database. Separations, mortality,
length of stay, presenting comorbidity and the
month of death were reported, stratiﬁed by age and
gender where appropriate.
The analyses took the form of descriptive statistics.
Conﬁdence intervals for the death rates post asthma
admission were created assuming a binomial distribu-
tion using the ‘Exact’ method (5). Binomial
distribution is considered more appropriate than a
normal distribution when the data is skewed and there
are only a few cases. The number of deaths per number
of separations was converted into deaths per 100,000
separations. Analyses were conducted using STATA
V9.2 (Stata Corporation, College Station, TX, USA).
Results
The numbers of asthma hospital events (separations)
are shown in Table 1 by type of admission. It can be
seen that for all codes, emergency (care within 24 h)
Table 1 Acute admissions by asthma code, 2000–2001 to 2004–2005 inclusive
Day case Not day case
Elective Emergency Unknown Elective Emergency Unknown
J46 101 4926 18 1724 30,316 406
J45 1808 29,882 201 8994 122,442 1788
Total 1909 34,808 219 10,718 152,758 2194
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ber of deaths over the 5-year period for all codes
combined equalled 289 from 202,739 asthma hospital
separations or 0.14%. Table 2 shows the mortality
rate per 100,000 separations and the data indicate
that when considered as a rate, males have a higher
rate in the 17–44 age group than females, particularly
so in the J46-coded patients. This is not observed in
the older patients over 45 years of age. For the
assessment of mortality throughout the year only
adult data were used as paediatric death was consid-
ered too rare to assess any monthly patterns. Figure 1
illustrates that July, September and January have the
highest rates.
The secondary comorbidities of patients admitted
with asthma are shown in Table 3. For all admis-
sions, acute upper respiratory infections were the
most common comorbidity. Length of stay for those
patients who died and those who were subsequently
discharged are shown in Table 4. Mean data are pro-
vided to inform health economics as total resource
use must be documented and the mean is the only
method suitable for measuring the average for total
values. Patients who died had longer average stays
than those who were discharged.
Discussion
This database analysis shows that mortality in asthma
patients after a hospital admission occurs predomi-
nantly in older patients over 45 years of age. How-
ever, the principle area of asthma burden to the
health system lies in the emergency or urgent admis-
sions requiring care within 24 h, which occurred in
large numbers, relative to all admissions for asthma
throughout Australia during the 5-year observation
period. A weakness of any database analysis is
the reliance on aggregated coded data, where coding
Table 2 Mortality rate per 100,000 separations by gender and age group 2001–2001 to 2004–2005 inclusive
Age band (years)
J46 J45
Male rate (95% Cl) Female rate (95% Cl) Male rate (95% Cl) Female rate (95% Cl)
0–11 n.p. n.p. n.p. n.p.
12–16 n.p. n.p. 0 0
17–44 900 (571; 1347) 351 (211; 547) 80 (38; 147) 44 (22; 79)
45 and over 1178 (748; 1763) 1116 (839; 1454) 318 (222; 442) 329 (266; 401)
n.p., numbers < 5 so data not presented.
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Figure 1 Month of death for adult asthma patients who died postadmission 2000–2001 to 2004–2005 (the rate is taken as
the mean average across the 5-year observation period)
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surprising to see that some J46 status asthmaticus
events were additionally coded as elective i.e. not an
emergency. We cannot check if this is an error or
the correct coding of patients admitted with status
asthmatics but not considered to require emergency
admission by the attending physician. However, we
believe that this database is no more or less reliable
than any other and additionally that it provides a
reasonable overview of asthma admissions within
Australia and the subsequent burden to the health
system.
The majority of these were inpatient stays and due
to some patients with very long stay, the mean stay
was up to 10 days in those patients who subse-
quently died, and 3 days in those who were dis-
charged. This clearly has high cost impact on the
health system and is supported by Kenny et al. (3)
who reported that in Australia, most of the health
system burden consisted of inpatient hospital care.
Kenny also reported that the costs attributed to
asthma were skewed by some individuals who had
very high per capita costs, the distribution thus rang-
ing from AUS $0 to $4882 per annum. Whilst this
study only reports at the event level rather than
patient level because of data aggregation, it is likely
that a proportion of patients will have repeated
attendance at the hospital and contribute greatly to
cost. This has been found in other studies about
emergency asthma admissions and fatal asthma,
where a risk factor for death or emergency admission
were prior admissions (6,7). Why patients may
repeatedly require admission is not assessed here, but
has previously been suggested in the TENOR study
to be due to poor control in moderate-to-severe
asthma patients (8). The TENOR study reported that
severe asthma patients have the highest healthcare
utilisation with 5% of adults and 10% of children
having experienced hospitalisation in the last
3 months and up to 13% having required intubation.
Vollmer et al. (9) also reported that acute healthcare
utilisation was three times more likely when patients
had control problems. The ﬁndings in this study also
support Simonella’s assertion that an optimal treat-
ment model with at an investment of AUS $627 mil-
lion would avert 69% of the disease burden (4).
Whilst this model costed investment at 39% more
than the current cost of treatment, it was offset by a
greater than twofold increase in health beneﬁt, with
emergency department and hospital separations esti-
mated to decrease by 28%. Optimal treatment would
also include general practitioner (GP) adherence to
guidelines and re-identiﬁcation of GPs priorities for
delivery of asthma care, which has been reported to
be discordant in Australia (10).
This study reports a slightly lower mortality rate
than a recent study examining UK mortality post
asthma admission, at 0.14% of all asthma admissions
vs. 0.43% in the UK (11). A US study also reported
in-hospital mortality post asthma admission at 0.5%
(12). Thus, whilst the majority of Australian asthma
patients are successfully managed in hospital, some
still die. Mortality may have many contributory
Table 3 Secondary comorbidities listed in 3% or more of patients admitted with asthma in the year 2004–2005
Secondary comorbidity code
Asthma
admission
code
Number of
patients with
comorbidity
% of patients
comorbidity
Asthma
admission
code
Number of
patients with
comorbidity
% of patients
comorbidity
J06 acute upper respiratory infections J46 905 17.2 J45 8132 25.3
Z71 medical advice or counselling J46 715 13.6 J45 0 0
Z72 problems related to lifestyle J46 460 8.7 J45 3103 9.6
Z86 personal history of certain other diseases J46 257 4.9 J45 1751 5.4
110 essential primary hypertension J46 195 3.7 J45 1355 4.2
J22 unspeciﬁed acute lower
respiratory tract infection
J46 188 3.6 J45 1712 5.3
E11 type 2 diabetes J46 188 3.6 J45 1484 4.6
J96 respiratory failure J46 162 3.1 J45 0 0
Table 4 Length of stay for patients admitted with
asthma between 2000–2001 and 2004–2005
Mean SD Median IQR
Length of stay for patients who died post asthma admission
J46 8.6 15.1 3 5.5
J45 10.8 15.3 5 10
Length of stay for patients discharged post asthma admission
J46 3.1 4.9 2 3
J45 2.7 3.3 2 2
SD, standard deviation; IQR, interquartile range.
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ethnicity, severity, triggers, treatment and so on,
which have been shown in other studies to impact
on mortality rates (7,12,13). Those patients that died
were mainly from the older age group aged over
45 years, a ﬁnding supported by the UK and US
studies which also found mortality to be far higher
in the older patients (11,12). Comorbidities experi-
enced by these patients may have contributed to
death or certainly caused the asthma exacerbation.
Upper respiratory tract infection, experienced in this
study by up to 25% of patients, has been previously
related to near fatal asthma and exacerbations (14).
Ten Brinke et al. (13) found that comorbidities con-
tributed to exacerbations in 136 severe asthma
patients, particularly repeated respiratory tract
infections, which was the second highest risk for
frequent excerbations [OR 6.9 (95% CI: 1.9–24.7)],
behind psychological dysfunctioning [OR 10.8
(95% CI: 1.1–108.4)], which may have been caused
by the asthma rather than contributing to the exacer-
bation rate.
Slightly more deaths occurred in the Australian win-
ter months (June through to September) with another
small peak in January (mid-summer). There is no clear
pattern, however, for asthma deaths as observed
elsewhere and it is hard to relate them to cause such as
the respiratory virus seasons which is more clearly
observable in the northern hemisphere (11).
This study has shown that in Australia the major
burden to the hospital system from asthma is emer-
gency hospital admission and subsequent stay.
Asthma-related mortality remains a risk for speciﬁc
patients within the hospital setting. Mortality occurs
mainly in older adults and the contributory effect of
comorbidities suffered by these patients requires fur-
ther investigation.
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